Both types 1 and 2 of the human immunodeficiency virus (HIV) are etiological agents for AIDS. Considerable efforts are devoted to the study of HIV proteases because of their potential as therapeutic targets in the treatment of AIDS. In addition to the extensive biochemical and genetic studies of HIV-1 protease (5, 6, 12, 13), its crystal structure was also solved (10, 17) . The sequences of HIV-1 and HIV-2 proteases are less than 50% identical; nevertheless, their enzymatic properties are generally very similar (11, 15, 16) . It has been proposed that the folding of the two proteases is similar (15) . However, in the absence of a crystal structure for HIV-2 protease, the above hypothesis has not been verified.
We and others have recently shown that the one-chain HIV-1 protease dimers, consisting of two copies of the HIV-1 protease monomer linked via 2 to 5 amino acids in a head-to-tail fashion, function equivalently to the natural two-chain HIV-1 protease dimer (4, 7) . In this study, we used a similar strategy to construct an active one-chain HIV-2 protease dimer. We then modified the HIV-1 and HIV-2 one-chain dimer constructs to produce polypeptides consisting of linked HIV-1 and HIV-2 monomeric subunits. These one-chain hybrid dimer proteases are fully active, suggesting that the folding of HIV-1 and HIV-2 protease monomers is functionally similar, so that subunit exchanges have no apparent effect on enzymatic activities.
Constructions for the expression of one-chain HIV protease dimers. The constructs for the HIV-1 and HIV-2 protease genes and the one-chain HIV-1 protease dimer were reported previously (2-4). We will use the same nomenclature as described previously for the HIV protease genes and their protein products. B represents the HIV protease N-terminal flanking sequences, and A represents the HIV protease coding sequences (2-4). The subscripts 1 and 2 represent sequences from HIV-1 (HXB2) and HIV-2 (ROD), respectively. For example, gene B2A2 (Fig. 1 ) has a DNA sequence spanning nucleotides 1931 to 2380 of the HIV-2 (ROD) genome, containing 51 codons of the N-terminal flanking sequence and 99 codons of the HIV-2 protease (3, 9). Gene B2A2 was modified to replace the 51 codons of the N-terminal flanking sequence with ACTTCGAGCTCAGGC, which * Corresponding author. has a unique SstI site. The modification was done by the polymerase chain reaction, using 2 oligonucleotides: ACT TCGAGCTCAGGCCCTCAATTCTCTCTTTGGAAAAG ACCAGTA and GGTGAAGCTTACTATAGATTTAAT GACATGCCTAAG. The resulting modified DNA was called SstI-A2. Gene B2A2 was also modified by the polymerase chain reaction with 2 oligonucleotides (TCGAATTCAT GTCCAGCAGTGGATCTACTGG and TAATGAGCTCC CTCCTAGATTTAATGACATGCCTAAGGCTGTCAG) to append the 3' end of gene B2A2 with GGAGGGAGCTCA TTA, which also carries a unique SstI site. The modified DNA was called B2A2-SstI. These two intermediates, B2A2-SstI and SstI-A2, were digested with SstI and ligated, resulting in a gene called B2A2A2. Gene B2A2A2 has 783 nucleotides, starting with GAATTCATG and the 51 codons for the N-terminal flanking sequence of HIV-2 protease shown as a thin line in Fig. 1 . The above sequence is followed with 99 HIV-2 protease codons (nucleotides 2084 to 2381), a 5-codon linker (GGAGGGAGCTCAGGC [for Gly-Gly-Ser-Ser-Gly]), another copy of the 99 HIV-2 protease codons, 2 stop codons, and a sequence for a HindIII site. The gene B2A2A2 was expressed in Escherichia coli as a 258-amino-acid precursor protein, which was quickly processed to the mature 203-amino-acid one-chain HIV-2 protease dimer (data not shown).
The basic construction of B2A2A2 for the one-chain HIV-2 dimer is the same as that of the one-chain HIV-1 dimer (4). In addition, identical linker sequences, joining the two protease monomeric sequences, were built in both one-chain dimer genes. Within the linker sequence, there is a unique SstI restriction site which was used to construct hybrid one-chain dimer genes. The larger fragment of the EcoRISstI-digested B,A,A, was ligated with the smaller fragment of the SstI-HindIII-digested B2A2A2 to generate the gene B,A,A2, which was used to produce a mature hybrid onechain dimer consisting of an HIV-1 protease at the N-terminal half and an HIV-2 protease at the C-terminal half (Fig. 1) .
Similarly, a ligation of the larger fragment of the EcoRI-SstIdigested B2A2A2 and the smaller fragment of the SstIHindIll-digested B,A,A, resulted in gene B2A2A, (Fig. 1 ).
All constructs were verified by DNA sequence analyses.
Later, the EcoRI-HindIII fragments of these genes were inserted into the expression vector pET3AM, regulated by a T7 promoter, as previously described (2, 14) .
Isolation and purification of HIV proteases. All six constructs were expressed under identical conditions for the production of precursor proteins as initial translation products. As shown previously, mature HIV proteases are generated by the removal of the N-terminal flanking peptide from the protease precursors by autoproteolysis (2-4). The expected protein sizes for the precursor and the mature forms are shown in Fig. 1 . Both the precursor and the mature forms were detectable in cell extracts of every one of the six constructs (data not shown). Only the mature forms were isolated for further studies. To simplify the names for these mature proteases, the natural HIV-1 and HIV-2 proteases expressed by genes B,A, and B2A2 are called PR-A1 and PR-A2, respectively. Similarly, their one-chain dimers are called PR-A1A1 and PR-A2A2, respectively. The hybrid one-chain protease dimer with HIV-1 protease at the N terminus and HIV-2 protease at the C terminus is called PR-A1A2, whereas the one with HIV-2 protease at the N terminus and HIV-1 protease at C terminus is called PR-A2A1. As described previously, both the natural HIV-1 protease (PR-A1) and its one-chain dimer (PR-A1Aj) were produced exclusively as insoluble inclusion bodies (2, 4). In contrast, both the HIV-2 natural protease (PR-A2) and its one-chain dimeric form (PR-A2A2) were totally soluble. It is interesting to note that the hybrid dimers produced in E. coli cells were found as both soluble and insoluble forms, at a roughly one-to-one ratio. The predicted pl values for HIV-1 and HIV-2 one-chain dimers are 9.30 and 5.10, respectively. column chromatography (Fig. 2, lanes 1 and 2) . This protocol was also used for the purification of PR-A1A2 and Pr-A2A1 isolated from inclusion bodies (Fig. 2, lanes 5 and  6) . The one-chain HIV-2 protease PR-A2A2 was purified from cell extracts by pepstatin-Sepharose and Mono-S fastprotein liquid chromatography (Fig. 2, lanes 3 and 4) according to a protocol previously used for the purification of HIV-2 protease (3). This protocol was also used successfully to purify PR-A1A2 and PR-A2A1 isolated from soluble cell extracts (data not shown). N-terminal sequence analyses were conducted with every one of the six HIV proteases, and the expected sequences were obtained with each of the purified proteases.
Enzymatic activities of the purified proteases. The primary translation product of B,A,A, in E. coli is a precursor polypeptide with a scissile bond between the N-terminal flanking peptide and the protease coding sequences of HIV-1. This scissile bond was autoproteolyzed in E. coli and in cell-free systems (4) , resulting in the formation of a mature one-chain dimer, PR-A1Al. Similarly, mature hybrid onechain dimers PR-A1A2 and PR-A2A1 were made from B,A,A2 and B2A2AJ constructs, which synthesized precursors with scissile bonds of HIV-1 and HIV-2 sequences, respectively. Therefore, both hybrid dimers can efficiently autoproteolyze the scissile bonds with either HIV-1 or HIV-2 sequences.
We also tested the cleavage of the HIV-1 P655a"' by these recombinant proteases. Figure 3 shows that the HIV-2 one-chain dimer (lane 5) and the hybrid HIV-1 and HIV-2 one-chain dimers (lanes 6 and 7) all effectively proteolyzed HIV-1 Pr559a9 to P24 in a manner qualitatively identical to the proteolysis by HIV-1 protease, its one-chain dimer, and HIV-2 protease (Fig. 3, lanes 1, 2, and 4) .
For a quantitative comparison of these proteases, we measured the kinetic constants of these proteases on a peptide substrate, Ala-Thr-His-Gln-Val-Tyr-Phe-(NO2)-ValArg-Lys-Ala. The results are summarized in Table 1 . Kinetic constants were determined at pH 5.5 and 1.0 M NaCl by the procedure described previously (4) PR-A1Aj and PR-A2A2 (Table 1) .
We have previously established that the biochemical properties of the one-chain HIV-1 protease dimer are very similar to those of the natural HIV-1 protease (4). We show in this report that the HIV-2 protease one-chain dimer can also be produced; its enzymatic activity is also very similar to that of the natural form.
Previous study indicated that the function of both linked monomers is needed to constitute an active enzyme. When single amino alterations were made at the active site of one of the two monomers of the one-chain dimer, completely inactive proteases resulted (4) . Nevertheless, the hybrid one-chain dimer proteases consisting of tethered HIV-1 and HIV-2 protease monomers, which are less than 50% identical in sequence, are fully active. This result suggests that in spite of their obvious sequence differences, the HIV-1 and the HIV-2 protease monomers are folded in a functionally similar manner. It is interesting to note that the kcatlKm values of the hybrid dimers are roughly the mean of those of the HIV-1 and HIV-2 one-chain dimeric proteases, suggesting that both linked monomers contribute the activity of the hybrid forms. To our knowledge, this is the first report comparing the folding properties of two dimeric proteins by functional comparison of the hybrid one-chain dimers of their constituent monomers.
Babe et al. recently observed a reduction of expected protease activity in a mixture of HIV-1 and HIV-2 proteases (1). This was interpreted as an inhibition of HIV protease activity by the formation of a noncovalent heterodimer which may display a disordered dimer interface, thereby affecting the catalytic potential of the enzymes (1). This interpretation, however, is complicated by their observation NOTES 1231 that heterogeneous protein species were found in the mixtures of the incubated HIV-1 and HIV-2 proteases. The natures of these heterogeneous protein species were not known, nor were their contributions to the overall protease activity assessed. In contrast, our hybrid one-chain dimers, which are single-species and biochemically defined proteins, are highly active. The high specific activities of these hybrid one-chain dimers suggest that they are unlikely to have a disordered dimer interface as proposed by Babe et al. (1) . The covalent linkage of our one-chain dimers may contribute to the alignment and stability of dimer formation (4) . Nevertheless, the distance between the covalent dimer linkage and the major dimer interface suggests that the covalent stabilization effect is unlikely to be a major factor for the ordered nature of the dimer interface.
